PUBLICATIONS


Since 2010

 

Singh V, Dhar N, Pató J, Kolly GS, Korduláková J, Forbak M, Evans JC, Székely R, Rybniker J, Palčeková Z, Zemanová J, Santi I, Signorino-Gelo F, Rodrigues L, Vocat A, Covarrubias AS, Rengifo MG, Johnsson K, Mowbray S, Buechler J, Delorme V, Brodin P, Knott GW, Aínsa JA, Warner DF, Kéri G, Mikušová K, McKinney JD, Cole ST, Mizrahi V, Hartkoorn RC.(2016) Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria, Mol Microbiol.

 

Singh V, Donini S, Pacitto A, Sala C, Hartkoorn RC, Dhar N, Keri G, Ascher DB, Mondésert G, Vocat A, Lupien A, Sommer R, Vermet H, Lagrange S, Buechler J, Warner DF, McKinney JD, Pato J, Cole ST, Blundell TL, Rizzi M, Mizrahi V. (2016) The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis. ACS Infect Dis

 

Degiacomi G, Personne Y, Mondésert G, Ge X, Mandava CS, Hartkoorn RC, Boldrin F, Goel P, Peisker K, Benjak A, Barrio MB, Ventura M, Brown AC, Leblanc V, Bauer A, Sanyal S, Cole ST, Lagrange S, Parish T, Manganelli R. (2016), Micrococcin P1 - A bactericidal thiopeptide active against Mycobacterium tuberculosis. Tuberculosis (Edinb). 100:95-101.

 

Mori G, Chiarelli LR, Esposito M, Makarov V, Bellinzoni M, Hartkoorn RC, Degiacomi G, Boldrin F, Ekins S, de Jesus Lopes Ribeiro AL, Marino LB, Centárová I, Svetlíková Z, Blaško J, Kazakova E, Lepioshkin A, Barilone N, Zanoni G, Porta A, Fondi M, Fani R, Baulard AR, Mikušová K, Alzari PM, Manganelli R, de Carvalho LP, Riccardi G, Cole ST, Pasca MR. (2015) Thiophenecarboxamide Derivatives Activated by EthA Kill Mycobacterium tuberculosis by Inhibiting the CTP Synthetase PyrG., Chem Biol. 23;22(7):917-27.

 

Tantry SJ, Degiacomi G, Sharma S, Jena LK, Narayan A, Guptha S, Shanbhag G, Menasinakai S, Mallya M, Awasthy D, Balakrishnan G, Kaur P, Bhattacharjee D, Narayan C, Reddy J, Naveen Kumar CN, Shandil R, Boldrin F, Ventura M, Manganelli R, Hartkoorn RC, Cole ST, Panda M, Markad SD, Ramachandran V, Ghorpade SR, Dinesh N.(2015), Whole cell screen based identification of spiropiperidines with potent antitubercular properties. Bioorg Med Chem Lett.25(16):3234-45.

 

Makarov V, Neres J, Hartkoorn RC, Ryabova OB, Kazakova E, Šarkan M, Huszár S, Piton J, Kolly GS, Vocat A, Conroy TM, Mikušová K, Cole ST. (2015) The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis. Antimicrob Agents Chemother. 59(8):4446-52

 

Vocat A, Hartkoorn RC, Lechartier B, Zhang M, Dhar N, Cole ST, Sala C. (2015) Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother. 59(7):4012-9

 

Sipos A, Pató J, Székely R, Hartkoorn RC, Kékesi L, Őrfi L, Szántai-Kis C, Mikušová K, Svetlíková Z, Korduláková J, Nagaraja V, Godbole AA, Bush N, Collin F, Maxwell A, Cole ST, Kéri G. (2015) Lead selection and characterization of antitubercular compounds using the Nested Chemical Library. Tuberculosis (Edinb). 95 Suppl 1:S200-6.

 

Neres J, Hartkoorn RC, Chiarelli LR, Gadupudi R, Pasca MR, Mori G, Venturelli A, Savina S, Makarov V, Kolly GS, Molteni E, Binda C, Dhar N, Ferrari S, Brodin P, Delorme V, Landry V, de Jesus Lopes Ribeiro AL, Farina D, Saxena P, Pojer F, Carta A, Luciani R, Porta A, Zanoni G, De Rossi E, Costi MP, Riccardi G, Cole ST. (2015) 2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1. ACS Chem Biol.10(3):705-14.

 

Rybniker J, Chen JM, Sala C, Hartkoorn RC , Vocat A, Benjak A, Boy-Röttger S, Zhang M, Szekely RE, Greff Z, Örfi L, Szabadkai I, Pató J, Kér G, Cole ST (2014) Anticytolytic screen identifies inhibitors of mycobacterial virulence protein secretion. Cell Host & Microbe 8;16(4):538-48.

 

Albesa-Jové D, Chiarelli LR, Makarov V, Pasca MR, Urresti S, Mori G, Salina E, Vocat A, Comino N, Mohorko E, Ryabova S, Pfieiffer B, Lopes Ribeiro AL, Rodrigo-Unzueta A, Tersa M, Zanoni G, Buroni S, Altmann KH, Hartkoorn RC, Glockshuber R, Cole ST, Riccardi G, Guerin ME. (2014) Rv2466c Mediates the Activation of TP053 To Kill Replicating and Non-replicating Mycobacterium tuberculosis. ACS Chem Biol. 18;9(7):1567-75.

 

Hartkoorn RC, Uplekar S, Cole ST (2014) Cross-resistance between Clofazimine and Bedaquiline through Up-regulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58(5):2979-81

 

Hartkoorn RC, Ryabova OB, Chiarelli LR, Riccardi G, Makarov V, Cole ST (2014) The mechanism of action of 5-nitrothiophenes against Mycobacterium tuberculosis. Antimicrob Agents Chemother 58(5):2944-7

 

Kolly GS, Boldrin F, Sala C, Dhar N, Hartkoorn RC, Ventura M, Serafini A, McKinney JD, Manganelli R, Cole ST (2014) Assessing the Essentiality of the Decaprenyl-phospho-D-arabinofuranose Pathway in Mycobacterium tuberculosis using Conditional Mutants. Mol Microbiol 92(1): 194–211

 

Hartkoorn RC, Pojer F, Read JA, Gingell H, Neres J, Horlacher OP, Altmann KH, Cole ST (2014) Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA. Nat Chem Biol 10: 96–98

 

Makarov V, Lechartier B, Zhang M, Neres J, van der Sar AM, Raadsen SA, Hartkoorn RC, Ryabova OB, Vocat A, Decosterd LA, Widmer N, Buclin T, Bitter W, Andries K, Pojer F, Dyson PJ, Cole ST (2014) Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol Med 6: 372-383

 

Horlacher OP, Hartkoorn RC, Cole ST, Altmann KH (2013) Synthesis and Antimycobacterial Activity of 2,1 '-Dihydropyridomycins. ACS Med Chem Lett 4: 264-268

 

Hartkoorn RC, Sala C, Neres J, Pojer F, Magnet S, Mukherjee R, Uplekar S, Boy-Rottger S, Altmann KH, Cole ST (2012) Towards a new tuberculosis drug: pyridomycin - nature's isoniazid. EMBO Mol Med 4: 1032-1042

 

Hartkoorn RC, Sala C, Uplekar S, Busso P, Rougemont J, Cole ST (2012) Genome-Wide Definition of the SigF Regulon in Mycobacterium tuberculosis. J Bacteriol 194: 2001-2009

 

Zhang M, Sala C, Hartkoorn RC, Dhar N, Mendoza-Losana A, Cole ST (2012) Streptomycin-Starved Mycobacterium tuberculosis 18b, a Drug Discovery Tool for Latent Tuberculosis. Antimicrob Agents Chemother 56: 5782-5789

 

Lechartier B, Hartkoorn RC, Cole ST (2012) In Vitro Combination Studies of Benzothiazinone Lead Compound BTZ043 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 56: 5790-5793

 

Blasco B, Chen JM, Hartkoorn R, Sala C, Uplekar S, Rougemont J, Pojer F, Cole ST (2012) Virulence Regulator EspR of Mycobacterium tuberculosis Is a Nucleoid-Associated Protein. PLoS Pathog 8

 

Sala C, Hartkoorn RC (2011) Tuberculosis drugs: new candidates and how to find more. Future Microbiol 6: 617-633

 

Sala C, Dhar N, Hartkoorn RC, Zhang M, Ha YH, Schneider P, Cole ST (2010) Simple Model for Testing Drugs against Nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 54: 4150-4158 2

 

Magnet S, Hartkoorn RC (joint first author), Szekely R, Pato J, Triccas JA, Schneider P, Szantai-Kis C, Orfi L, Chambon M, Banfi D, Bueno M, Turcatti G, Keri G, Cole ST (2010) Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis (Edinb) 90: 354-360

 

Hartkoorn RC, Sala C, Magnet SJ, Chen JM, Pojer F, Cole ST (2010) Sigma Factor F Does Not Prevent Rifampin Inhibition of RNA Polymerase or Cause Rifampin Tolerance in Mycobacterium tuberculosis. J Bacteriol 192: 5472-5479

 

Hartkoorn RC, San Kwan W, Shallcross V, Chaikan A, Liptrott N, Egan D, Sora ES, James CE, Gibbons S, Bray PG, Back DJ, Khoo SH, Owen A (2010) HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 20: 112-120